Redeye concludes that Railcare had a solid start to the year.
Redeye considers Arise’s Q1 2024 report to be better than expected, as the production segment manage...
Redeye provides its initial comments on the Q1 2024 report from Scandinavian Chemotech, which was br...
Redeye saw a report where the first sales were reported for Terclara, and the cost aligned with expe...
Redeye notes that Q1 sales were slightly lower than our estimates; however, EBIT aligned with our fo...
Flattish sales on tough comps, EBITA +31% vs cons on higher GM Stabilised market with improvements i...
Redeye comments on I-Tech’s Q1 figures beating our expectations across the board.
43% beat on EBIT Expected launch of new product delayed EBIT '24e expected to be revised up 7-10% Q...
Sales +24% and EBIT +52% vs. consensus Strong quarter with record-high turnover and profit Outlook r...
Redeye will likely increase its forecasts and Base Case following a strong Q1 report, with high gros...
Net sales and clean EBIT were below market consensus (LSEG) in Q1.
21% EBITA beat vs. consensus mainly margin-driven Lower costs and favourable mix to persist, EBITA u...
Redeye sees a softer Q1 report from Hanza than expected.
NoHo Partners reported Q1 EBIT of EUR 6.9m, 2% above Vara consensus and our estimate.
Taaleri reported Q1 EBIT of EUR 9.6m, coming well in line with LSEG Data & Analytics consensus at EU...
Redeye revises its estimates following the Q1 2024 report, which came in above our expectations in t...
Redeye maintains its optimistic outlook post the Q1 2024 report despite slightly lower sales and pro...
Redeye states that Catella delivered a quarter mostly in line with estimates, showing impressive cos...
Redeye comments on Alligator Bioscience's Q1 report, including the sub-optimal funding situation aft...
Seamless Distribution Systems (”SDS” eller ”bolaget”) publicerade den 3 maj 2024 bolagets delårsrapp...
